Depatuxizumab
- Generic Name
- Depatuxizumab
- Drug Type
- Biotech
- CAS Number
- 1471999-69-5
- Unique Ingredient Identifier
- W984C353CG
- Background
Depatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
KN026 Plus Docetaxel Shows Promise in HER2+ Metastatic Breast Cancer
• A Phase 2 trial of KN026 plus docetaxel shows a 76.4% objective response rate in HER2+ metastatic breast cancer patients.
• The combination therapy resulted in a median progression-free survival of 27.7 months, indicating a potential first-line treatment option.
• The study reports a manageable safety profile, with no deaths attributable to KN026 or docetaxel, suggesting a favorable cardiac safety profile.
• A Phase 3 trial is planned to further evaluate the efficacy and safety of KN026 in combination with HB1801 for HER2+ metastatic breast cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath